Myositis Treatment Market size was valued at USD 650 Million in 2023 and is projected to exceed USD 1.1 Billion by the end of 2036, expanding at over 4.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of myositis treatment is evaluated at USD 686.2 Million.. The major factor for market growth is the rising cases of myositis among the global population. For instance, in the United States, an estimated 1,600 to 3,200 new cases of myositis are detected every year. Also, it has been observed that 50,000 to 75,000 people are already being diagnosed and living with myositis in the same region. Thus, the rising cases of myositis are expected to generate demand for its treatment and expand its market size during the forecast period.
The global myositis treatment market is attributed to growth on account of rising inflammation in muscles owing to infection, injury, and autoimmune disease across the world. Furthermore, the prevalence of viral infections and high consumption rate of statins, cocaine, and alcohol is aiding myositis in the global population and the expansion of the market size during the assessment period. Also, the burgeoning geriatric population who are more prone to inflammation in muscles and other musculoskeletal diseases is expected to increase the demand for myositis treatment in the world. In addition to the other factors mentioned, the increasing awareness level about myositis disease along with its different types, symptoms, causes, and others, and the easy availability of treatment and cure procedures is also estimated to bring in lucrative growth opportunities for the market growth. Moreover, the recent advancement in technology has propelled a faster production rate of novel drugs and medical devices and is projected to impetus a significant revenue generation from the global myositis treatment market during the forecast period. The emergence of new modern therapies in the healthcare industry along with the high investments by major key players to bridge the gap between supply and demand of medications and therapies is also anticipated to create a positive outlook for market growth.
Growth Drivers
Growing Cases of Musculoskeletal Diseases Amongst Global Population – Musculoskeletal diseases are often characterized by prolonged pain in muscles of the human body which limit the mobility and dexterity of an individual. Such diseases lead to inflammation and weakness in muscles with pain and ache. Thus, the increase in cases of musculoskeletal diseases is anticipated to drive the global myositis treatment market in the upcoming years. As per the statistics shared by the World Health Organization (WHO) in 2022, approximately 1.71 billion people are affected by musculoskeletal conditions all over the world.
Rapid Surge in Occurrence of Injuries – Different types of injuries are encountered by humans owing to accidents, traumas, and injuries. The National Safety Council stated that in 2020, the United States experienced around 55.4 million injuries, out of which 200,955 were classified as preventable deaths. Such injuries can lead to myositis and subsequently increase the demand for myositis treatment and drive market growth.
Burgeoning Geriatric Population – Elderly people have weakened bodies and deteriorating body organs making them more prone to myositis. Hence, the expanding percentage of the geriatric population is estimated to create a positive outlook for market expansion. The World Health Organization (WHO) stated that the population of elderly people in 2020 around the world was almost 1.4 billion which is forecasted to doubly increase and reach around 2.1 billion by 2050. It is also expected that by 2030, 1 in 6 people worldwide is estimated to be classified as elderly people.
Significant Rise in Healthcare Expenditure – With the growing economies, the spending capacity of people has also increased. This has propelled a high expenditure on the treatment of diseases such as myositis for fitness and health purposes. Therefore, the high healthcare expenditure is expected to expand the market size in the next few years. The World Bank revealed that healthcare expenditure increased from 9.7% of the total global GDP in 2018 to 9.83% of the total global GDP in 2019.
Adoption of Sedentary Lifestyle – Owing to the busy lifestyle, people are shifted towards more inactivity and less physical activity. As a result, people nowadays are more prone to diseases and disorders such as myositis. This factor is attributed to the growth of the global myositis treatment market during the forecast period. Recent statistics shared by the World Health Organization (WHO) in 2018 stated that 1 in 4 adults which is equivalent to 28% or 1.4 billion are physically inactive.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.2% |
|
Base Year Market Size (2023) |
USD 650 Million |
|
Forecast Year Market Size (2036) |
USD 1.1 Billion |
|
Regional Scope |
|
Type (Dermatomyositis, Inclusion-Body Myositis, Juvenile Myositis, Polymyositis, Toxic Myositis)
The global myositis treatment market is segmented and analyzed for demand and supply by type into dermatomyositis, inclusion-body myositis, juvenile myositis, polymyositis, and toxic myositis. Out of these types of myositis, the polymyositis segment is estimated to gain the largest market share of about 28% in the year 2036. The major factor that is attributed to segment growth is the rising prevalence of polymyositis among the global population. The report published by the National Library of Medicine stated that the estimated prevalence of polymyositis is 5 to 22 per 100,000 persons, while incidence is around 19 per million at risk per year globally. Also, polymyositis is considered to be the most occurring type of myositis among the global population which is anticipated to create favorable opportunities for market growth. Also, polymyositis is common in individuals who do not seek timely medical health checkups and can cause disability if not cured with timely intervention, thus expanding market size. Furthermore, the presence of polymyositis in a number of clinical pipelines of key market players is also anticipated to fuel market growth in the forecast period.
End-user (Hospital, Homecare, Specialty Clinics)
The global myositis treatment market is also segmented and analyzed for demand and supply by end-user into hospitals, home care, specialty clinics, and others. Amongst these segments, the hospital segment is expected to garner a significant share of around 42% in the year 2036 with a significant CAGR value. The availability of hospitals in every region of the world along with the presence of advanced therapy medicinal products for the treatment of myositis is considered to be a major factor in the expansion of the segment. For instance, there were over 8,000 hospitals in Japan as of 2020. Korea, by contrast, had about 4,000 hospitals. In addition, there were more than 6000 hospitals in the United States. Also, the rising preference of hospitals for receiving treatment by the population owing to the accessibility of trained medical staff and professionals along with the rising investments to enhance hospital infrastructure and escalation in patient inflow for treatments are other factors that are attributed to positively contribute to segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End User |
|
North American Market Forecast
The North American myositis treatment market, amongst the market in all the other regions, is projected to hold the largest market share of about 37% by the end of 2036. The growth of the market can be attributed majorly to the increasing frequency of musculoskeletal disorders amongst several people, backed by the sedentary lifestyle of individuals. For instance, it has been calculated that the prevalence of musculoskeletal diseases in the United States is approximately 124 million people which accounts for 1 out of every two persons. Further, the high health awareness amongst the population, along with easy access to quality healthcare in the developed region is attributed to rapid market expansion in the region during the forecast period. In addition, the region's expanding healthcare industry and rising healthcare expenditure are also anticipated to boost the market growth in the upcoming years.
APAC Market Statistics
The Asia Pacific myositis treatment market, amongst the market in all the other regions, is projected to hold the second largest share of about 31% during the forecast period. The growth of the market can be attributed majorly to the increasing frequency of various chronic muscle diseases and prolonged pain, ache, and infection among the people living in the region. According to a report from the World Health Organization (WHO), more than 369 million people suffer from muscle-related diseases in the South-East Asia region. Furthermore, the burgeoning geriatric population in the region who are more prone to myositis and is expected to expand the market size in the analysis period. Also, the rising focus on health and fitness coupled with government initiatives that promote a healthy lifestyle is anticipated to increase the adoption rate of myositis treatment.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The presence of a large pool of patients being diagnosed with various chronic and acute diseases leading to myositis is expected to increase the chances of myositis treatment in the upcoming years. Also, the high expenditure on health is anticipated to create a positive outlook for market growth in the region. Furthermore, the presence of favorable policies is anticipated to create a positive outlook for market expansion during the forecast period.
IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?